ACE-Dependent Alzheimer’s Disease: Circulating ACE Phenotypes in Heterozygous Carriers of Rare ACE Variants
Authors:
- Iaroslav V. MironenkoIaroslav V. Mironenko
- Olga V. KryukovaOlga V. Kryukova
- Anastasiia A. BuianovaAnastasiia A. Buianova
- Alexey V. ChurovAlexey V. Churov
- Mikhail S. ArbatskyMikhail S. Arbatsky
- Alyona A. KubrikovaAlyona A. Kubrikova
- Yunna S. PetrusenkoYunna S. Petrusenko
- Zhanna A. RepinskaiaZhanna A. Repinskaia
- Anna O. ShmitkoAnna O. Shmitko
- Galit A. IlyinaGalit A. Ilyina
- Olga A. KostOlga A. Kost
- Steven M. DudekSteven M. Dudek
Open Access
- 18 September 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9099
Abstract
Damaging mutations of the Angiotensin I-converting enzyme (ACE) that result in low ACE levels may increase the risk of developing late-onset Alzheimer’s disease (AD). We quantified blood ACE levels in EDTA-plasma from 147 subjects with 23 different heterozygous ACE mutations (and 70 controls) and estimated the effect of these mutations on ACE phenotype, using a set of monoclonal antibodies (mAbs) to ACE and two ACE substrates. We identified several mutations in both ACE domains (including the most frequent ACE mutation, Y215C), which led to decreased ACE levels in the blood, and thus could be considered as putative risk factors for late-onset AD. The precipitation of several ACE mutants (Q259R, A725P, C734Y) by specific mAbs changed significantly, and therefore, these mAbs could be markers of these mutations. Analysis of 50 of the most frequent ACE mutations demonstrates that more than 1.5% of the adult population may have mutations which lead to decreased ACE levels, and thus, the role of low ACE levels in the development of AD may be underappreciated. Intriguingly, statistical and cluster analyses of longevity patients revealed trends towards higher frequency of cognitive impairment among affected individuals with damaging ACE mutations. Systematic analysis of blood ACE levels in patients with various ACE mutations identifies individuals with low blood ACE levels who may be at increased risk for late-onset AD. Patients with transport-deficient ACE mutations theoretically could benefit from therapeutic treatment with a combination of chemical and pharmacological chaperones and proteasome inhibitors, as was demonstrated previously on a cell model of the transport-deficient ACE mutation Q1069R. Moreover, clinical association analysis suggests a trend linking damaging ACE mutations with increased risk of cognitive impairment.Keywords
This publication has 53 references indexed in Scilit:
- ACE-dependent Alzheimer's disease: Further assessment of the impact of ACE mutations on blood ACE levelsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2025
- Evaluating the association between genetically proxied ACE inhibition and dementiasAlzheimer's & Dementia, 2023
- Genetic profiles of familial late-onset Alzheimer's disease in China: The Shanghai FLOAD studyGenes & Diseases, 2021
- Epitope mapping of novel monoclonal antibodies to human angiotensin I‐converting enzymeProtein Science, 2021
- Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin systemPharmacological Research, 2020
- Conformational Fingerprinting of the Angiotensin I-Converting Enzyme (ACE). 1. Application in SarcoidosisJournal of Proteome Research, 2010
- ACE I/D-corrected Z-scores to identify normal and elevated ACE activity in sarcoidosisRespiratory Medicine, 2007
- Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer diseaseNature Genetics, 1999
- Presenilin polymorphisms in Alzheimer's diseaseThe Lancet, 1997
- Serum angiotensin converting enzyme activity in patients with chronic renal failure on long term hemodialysisClinica Chimica Acta, 1979